Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Vitrakvi

National Institute for Health and Care Excellence NICE logo

NICE denies two drugs in new MS guidance

Sativex and Fampyra too costly for NHS in England

- PMLiVE

Cancer Drugs Fund could take on a price assessment role

NHS England consults on a series of significant changes to Fund

- PMLiVE

Young diabetes patients in England and Wales receive fewer vital checks

Less than a third with type 1 diabetes receive eight of nine recommended care processes

- PMLiVE

NICE recommends Lundbeck’s alcohol dependency drug

NHS patients to have access to Selincro to help control drinking

- PMLiVE

Janssen backs NHS diabetes challenge

Will provide £200,000 to spread innovation across UK

National Institute for Health and Care Excellence NICE logo

Remicade, Humira and Simponi face NICE knock-back

Draft guidance does not recommend the drugs for ulcerative colitis

- PMLiVE

NICE backs Celgene’s Revlimid in rare blood cancer

Patient access scheme sways the HTA body

- PMLiVE

NICE fast-tracks GSK’s skin cancer drug Tafinlar

But only on condition the company cuts its price

National Institute for Health and Care Excellence NICE logo

NICE wants greater access to clinical data

Will turn to European regulators if companies fail to provide information

- PMLiVE

NICE knocks back Celgene’s Abraxane in pancreatic cancer

Says cancer drug's cost not justified by its limited benefit

- PMLiVE

England’s Cancer Drugs Fund: Naughty or NICE?

The decision to extend the CDF raises questions on the future of cancer drug access on the NHS

- PMLiVE

Alexion convinces NICE of Soliris’ value

But recommendation of the expensive 'ultra orphan' drug' comes with conditions

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links